The international conference “2nd Global Cardiology Summit” is accepting the valuable abstracts from expertise in cardiology and healthcare.
The conference is organized around the theme: Where the world of Cardiology and Healthcare comes together in Bangkok, Thailand from August 15-16, 2019.
We are happy to invite the research proposals for the following sessions:
Heart or cardiovascular disease has been increased in the current scenario. The most common cause of heart disease is the deposition of plaques build up inside the arteries, the blood vessels that carry oxygen-rich blood around your body. This is called atherosclerosis. White blood cells from the immune system collect at the plaque and cause inflammation.
The continuous deposition over the time may lead to narrowing of arteries. This limits the flow of oxygen-rich blood to your heart and other organs. Atherosclerosis can lead to serious problems, including heart attack, stroke, or even death.
Recent researches has found the link between sleep deficiency and certain sleep disorders, such as sleep apnea, to an increased risk of heart disease and other health conditions. But the molecular mechanisms underlying the link between sleep and heart disease has been still unknown.
Heart or cardiovascular disease has been increased in the current scenario. The most common cause of heart disease is the deposition of plaques build up inside the arteries, the blood vessels that carry oxygen-rich blood around your body. This is called atherosclerosis. White blood cells from the immune system collect at the plaque and cause inflammation.
The continuous deposition over the time may lead to narrowing of arteries. This limits the flow of oxygen-rich blood to your heart and other organs. Atherosclerosis can lead to serious problems, including heart attack, stroke, or even death.
Recent researches has found the link between sleep deficiency and certain sleep disorders, such as sleep apnea, to an increased risk of heart disease and other health conditions. But the molecular mechanisms underlying the link between sleep and heart disease has been still unknown.
The heart or cardiovascular disease is a leading cause for death all over the world. In recent years, heart transplantation is mostly for treating end stage heart failure.
Researchers from Tel Aviv University have “printed” the world’s first 3D vascularised engineered heart using patient’s own cells and biological materials. For the first time anyone anywhere has successfully engineered and printed an entire heart replete using cells, blood vessels, ventricles and chambers, given the dire shortage of heart donors, the need to develop new approaches to regenerate the diseased heart is urgent.
This heart is made from human cells and patient-specific biological materials. These materials serve as the bioinks, substances made of sugars and proteins that can be used for 3D printing of complex tissue models. In previous findings, people have managed to 3D-print the structure of a heart, but not with cells or with blood vessels. This approach demonstrate the potential for engineering personalized tissue and organ replacement in the future.
The printed heart now is small in size i.e. the size of a rabbit’s heart
For the research, a biopsy of fatty tissue was taken from patients. The cellular and a-cellular materials of the tissue were then separated. While the cells were reprogrammed to become pluripotent stem cells, the extracellular matrix (ECM), a three-dimensional network of extracellular macromolecules such as collagen and glycoproteins, were processed into a personalized hydrogel that served as the printing “ink.”
After being mixed with the hydrogel, the cells were efficiently differentiated to cardiac or endothelial cells to create patient-specific, immune-compatible cardiac patches with blood vessels and, subsequently, an entire heart.
Currently the 3D printed heart can only contract. The researchers still carrying out the research to enable the cells to form a pumping ability.
According to the results of a systematic review & meta-analysis, evidence supporting the clinical benefit of niacin monotherapy for secondary prevention of Cardiovascular Disease appears to be outdated and require various innovative trials to determine its role in CVD management.
Scientists performed a systematic review and meta-analysis to identify clinical trials assessing the effect of niacin on lipid modification and CVD risk To determine the role of niacin in CVD prevention.
The results from the study shows that while there is evidence to support the clinical benefit of niacin in the prevention of CVD, this evidence was obtained from older trials with study populations that most likely have differing baseline characteristics (i.e., underlying cardiovascular risk) compared to patient populations seen today. The authors concluded that “Niacin may have a role as a monotherapy drug for lipid control in statin-intolerant patients, but, given substantial advancements in cardiovascular disease management since 1990, this indication should be restudied in current-day patients receiving usual baseline care.”
Angiotensin II antagonists may help prevent GI bleeding among heart failure patients with continuous-flow left ventricular assist devices (LVADs), a study says.
Taking ACE inhibitors or angiotensin receptor blockers (ARBs) at any point within the first 30 days following LVAD placement was associated with a reduced subsequent risk of major GI bleeds.
The findings confirm those of a 2017 observational study linking ACE inhibitor/ARB therapy with reduced GI bleeding risk.
Continuous-flow LVADs are thought to cause GI bleeds through the hypoperfusion of the GI mucosa and subsequent angiogenesis that results in crumbly vessels prone to bleeding, the authors noted. “ACE inhibitor/ARB therapy may protect against angiogenesis by directly blocking angiotensin II formation or by antagonism of the angiotensin type 1 receptor.”
Submit such research to present at Cardiology Conferences 2019 held at Bangkok, Thailand from August 15-16, 2019.
2nd Global Cardiology Summit 